Pfizer

News

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).

News

Patients switch to lower dose of Pfizer's RA pill after safe...

Pfizer is moving rheumatoid arthritis patients to a lower dose of its blockbuster inflammatory diseases pill Xeljanz in a clinical study, after a safety signal emerged in the trial of patie

News

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from Johnson

News

Keytruda combo set to become "standard of care" in kidney ca...

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a pr

News

Merck/Pfizer up the pressure on BMS in first-line kidney can...

The FDA has started a speedy review of Merck KGaA and Pfizer’s new combination regimen for advanced kidney cancer, setting up a possible approval in June and piling more pressure on Bristol

Partner Content

An interview with Heiko Goette, Biostatistician, Merck

ahead of Adaptive Designs in Clinical Trials

More positive results for Pfizer/Lilly’s non-opioid pain dru...

Patients switch to lower dose of Pfizer's RA pill after safe...

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Keytruda combo set to become "standard of care" in kidney ca...

Merck/Pfizer up the pressure on BMS in first-line kidney can...

An interview with Heiko Goette, Biostatistician, Merck

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Pfizer

Editor's Picks